Background Allergic rhinitis (AR) is increasingly acknowledged as having a substantial
socioeconomic impact associated with impaired work productivity, although available …

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several
factors, including age, prominent symptoms, symptom severity, control of AR, patient …

Background The SQ HDM SLIT-tablet (ALK) has been developed for treatment of house dust
mite (HDM)–induced respiratory allergic disease. Objective This trial investigated the …

BACKGROUND: Moderate-to-severe allergic rhinitis (AR) is a challenge to treat, with many
patients using multiple therapies and achieving limited symptom control. More effective …

BACKGROUND: Sustained and disease-modifying effects of sublingual immunotherapy
have never before been confirmed in a large-scale randomized, double-blind, placebo …

This meta-analysis compared the health-related quality of life (HRQL) of patients with
allergic rhinitis (AR) and/or allergic asthma (AA) caused by perennial house dust mite (HDM) …

To cite this article: Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis
and the common cold–high cost to society. Allergy 2010; 65: 776–783. Abstract Background …

Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of
the current symptomatic treatments for AR have been available for decades, yet there has …

Background The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent
initiatives by the European Academy of Allergy & Clinical Immunology and by the EU …

Background: It is unclear what constitutes a clinically meaningful response for allergic
rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a …